| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $46,030,713 ) (Continued on the next page) |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA279749 | Integrating patient-reported outcomes and T-cell receptor sequencing to predict immune-related adverse events | 000 | 2 | NIH | 12/18/2024 | $591,407 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R34AT012360 | Randomized controlled trial to test feasibility of a culturally adapted meditation-based support intervention for Black patients dealing with advanced cancer | 002 | 3 | NIH | 1/9/2025 | $0 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R34AT012360 | Randomized controlled trial to test feasibility of a culturally adapted meditation-based support intervention for Black patients dealing with advanced cancer | 001 | 3 | NIH | 12/19/2024 | $218,700 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA202919 | Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer | 000 | 10 | NIH | 1/9/2025 | $336,677 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K22CA279077 | Enhancing the efficacy of immunotherapy by optimal use of SMAC mimetics | 000 | 2 | NIH | 11/1/2024 | $192,240 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA271223 | Dissemination and implementation of DIGEST™ as an evidence-based measurement tool for dysphagia in cancer | 000 | 3 | NIH | 1/24/2025 | $572,302 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278940 | Role of NSD3 in regulation of cancer pathogenesis | 000 | 3 | NIH | 3/5/2025 | $580,099 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01DE030875 | Functional roles of GOF TP53 mutations in metastasis and immunosuppression of head and neck cancers | 000 | 4 | NIH | 3/10/2025 | $500,532 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA277152 | Preclinical studies of non-nucleoside DNMT3A/3B inhibitors | 000 | 2 | NIH | 11/1/2024 | $170,405 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278967 | CRACD-controlled cell plasticity and small cell lung cancer | 000 | 2 | NIH | 11/22/2024 | $542,413 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278971 | Esophageal Squamous Cell Cancer Initiation and Immune Landscape Remodeling | 000 | 2 | NIH | 11/7/2024 | $468,540 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA279452 | Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor | 000 | 2 | NIH | 11/7/2024 | $604,615 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA286992 | Targeting MDM4 in Rare Refractory Ovarian Cancer Sub-Types | 000 | 2 | NIH | 11/1/2024 | $204,485 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA242565 | Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy | 000 | 6 | NIH | 12/31/2024 | $196,781 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01CA275886 | Identifying and targeting collateral lethal vulnerabilities in cancers | 001 | 3 | NIH | 3/12/2025 | $870,334 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01MD017999 | Health equity in fertility specialty care among cancer survivors | 000 | 3 | NIH | 12/17/2024 | $447,420 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278938 | Comparative Effectiveness of Sequential Pharmacotherapeutic Strategies and Virtually Delivered Treatment to Optimize Smoking Cessation | 000 | 2 | NIH | 12/23/2024 | $819,991 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01EB032533 | Enhanced Biomechanical Modeling of the Breast for Womens Health | 000 | 4 | NIH | 3/21/2025 | $525,446 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269565 | The Role of HIF2 in Pancreatic Ductal Adenocarcinoma | 001 | 3 | NIH | 1/14/2025 | $33,301 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269565 | The Role of HIF2 in Pancreatic Ductal Adenocarcinoma | 000 | 3 | NIH | 12/17/2024 | $515,400 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01DE032168 | Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-Enhanced MRI as a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI) | 000 | 3 | NIH | 3/11/2025 | $634,331 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA270010 | Exploring novel strategies for immunoprevention of estrogen receptor negative breast cancer | 000 | 3 | NIH | 2/12/2025 | $426,474 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R03CA289563 | Effect of SIRPalpha mismatch on the outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) from an HLA matched related donor | 000 | 2 | NIH | 3/19/2025 | $81,000 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R35GM149226 | Regulation of Overall Cell Numbers During Epithelial Tissue Homeostasis and Pathogenesis | 001 | 3 | NIH | 3/21/2025 | $379,080 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA262437 | ROLE OF SORD IN SUGAR-MEDIATED CANCER METASTASIS | 000 | 5 | NIH | 3/3/2025 | $324,064 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA275712 | Deciphering pathways involved in topoisomerase II turnover | 000 | 3 | NIH | 11/8/2024 | $452,669 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS132398 | Mechanisms of Epigenetic Plasticity in Neuropathic Pain | 000 | 3 | NIH | 3/10/2025 | $438,970 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS126252 | Regulation of Peripheral Neuropathic Pain by B Cells | 001 | 4 | NIH | 2/13/2025 | $484,813 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K22CA276360 | Unraveling the functional contribution of extracellular vesicles in pancreatic cancer | 000 | 1 | NIH | 12/20/2024 | $192,240 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA288901 | Proteomics-driven precision molecular mapping of patient tumors to preclinical models in lung cancer | 000 | 1 | NIH | 3/11/2025 | $244,228 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K08CA296776 | Harnessing ecDNA Detection in Antigen-Presenting Cells for Anti-Tumor Immunity | 000 | 1 | NIH | 1/14/2025 | $139,247 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA287279 | Deciphering the structural determinants of response and resistance to HER2-targeted antibody-drug conjugates and tyrosine kinase inhibitors for HER2-mutant Non-Small Cell Lung Cancer | 000 | 1 | NIH | 3/19/2025 | $695,004 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K99CA296940 | Adverse gut microbiome promotes resistance immune checkpoint inhibitors via chronic inflammation | 000 | 1 | NIH | 3/20/2025 | $32,400 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K99CA296780 | The role of oral microbiota in metastatic brain tumors | 000 | 1 | NIH | 3/10/2025 | $112,026 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA299972 | Deregulation of Sulfatide Synthesis in the Development and Progression of Pancreatic Cancer Precursor Lesions | 000 | 1 | NIH | 3/1/2025 | $616,495 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA295906 | Targeting SMARCA2 to overcome resistance of SMARCA4-mutant lung cancer to KRAS G12C inhibitors | 000 | 1 | NIH | 12/25/2024 | $267,527 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R35GM156417 | Computational and experimental approaches for decoding the function and regulation of unconventional RNA translation | 000 | 1 | NIH | 12/25/2024 | $449,625 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA301555 | Delivery optimization of a transarterial ablative therapy | 000 | 1 | NIH | 3/11/2025 | $536,836 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K99CA286745 | Mechanisms of CDH1-inactivated advanced gastric adenocarcinoma tumorigenesis | 000 | 1 | NIH | 1/20/2025 | $125,783 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA295834 | Endogenous Circular RNAs limit abemaciclib anti tumor immune responses | 000 | 1 | NIH | 3/17/2025 | $567,059 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01EB034665 | Single-use Microfluidic Device for Radiopharmaceutical Production | 000 | 1 | NIH | 2/25/2025 | $574,632 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21LM014699 | Novel designs for multi-arm multi-dose multi-stage platform trials | 001 | 1 | NIH | 3/11/2025 | $0 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21LM014699 | Novel designs for multi-arm multi-dose multi-stage platform trials | 000 | 1 | NIH | 12/26/2024 | $183,938 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA267856 | Improving emergency care and outcomes of immune-related adverse events: The immune-related emergency disposition index (IrEDi) | 000 | 4 | NIH | 12/18/2024 | $596,891 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS101880 | Molecular Determinants of Synaptic Plasticity in Chronic Pain | 000 | 8 | NIH | 11/21/2024 | $451,854 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R03DE033550 | Probabilistic Deep Learning Cervical Lymph-Node Auto-Segmentation For Imaging-enhanced Evaluation of Extracapsular Extension Risk (PDL-CLASIFIER) | 000 | 2 | NIH | 3/18/2025 | $145,800 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | F31HD113306 | Molecular and Cellular Regulation of Uterine Morphogenesis | 000 | 2 | NIH | 1/23/2025 | $36,960 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA276235 | Cis-aconitate decarboxylase (ACOD1) in PMN-MDSC and prostate cancer progression | 000 | 3 | NIH | 12/13/2024 | $333,518 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA288804 | A Novel Strategy of Targeting Transmembrane Protein to Improve KRAS-targeted Therapy | 000 | 2 | NIH | 2/13/2025 | $170,405 |
|
